We have previously identified the pyrazolobenzothiazine scaffold as a promising chemotype against hepatitis C virus (HCV) NS5B polymerase, a validated and promising anti-HCV target. Herein we describe the design, synthesis, enzymatic and cellular characterization of new pyrazolobenzothiazines as anti-HCV inhibitors. The binding site for a representative derivative was mapped to NS5B palm site I employing a mutant counter screen assay, thus validating our previous in silico predictions. Derivative 2b proved to be the best selective anti-HCV derivative within the new series, exhibiting IC50 value of 7.9 µM against NS5B polymerase and antiviral effect (EC50 = 8.1 µM, EC90 = 23.3 µM) coupled with the absence of any antimetabolic effect (CC50 >224 µM, SI >28) in a cell based HCV replicon system assay. Significantly, microscopic analysis showed that, unlike the parent compounds, derivative 2b did not show any significant cell morphological alterations. Furthermore, since most of the pyrazolobenzothiazines tested altered cell morphology, this undesired aspect was further investigated by exploring possible perturbation of lipid metabolism during compound treatment.
New Pyrazolobenzothiazine Derivatives As Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors
MANFRONI, GIUSEPPE;BARRECA, MARIA LETIZIA;CANNALIRE, ROLANDO;IRACI, NUNZIO;SABATINI, STEFANO;TABARRINI, Oriana;CECCHETTI, Violetta
2014
Abstract
We have previously identified the pyrazolobenzothiazine scaffold as a promising chemotype against hepatitis C virus (HCV) NS5B polymerase, a validated and promising anti-HCV target. Herein we describe the design, synthesis, enzymatic and cellular characterization of new pyrazolobenzothiazines as anti-HCV inhibitors. The binding site for a representative derivative was mapped to NS5B palm site I employing a mutant counter screen assay, thus validating our previous in silico predictions. Derivative 2b proved to be the best selective anti-HCV derivative within the new series, exhibiting IC50 value of 7.9 µM against NS5B polymerase and antiviral effect (EC50 = 8.1 µM, EC90 = 23.3 µM) coupled with the absence of any antimetabolic effect (CC50 >224 µM, SI >28) in a cell based HCV replicon system assay. Significantly, microscopic analysis showed that, unlike the parent compounds, derivative 2b did not show any significant cell morphological alterations. Furthermore, since most of the pyrazolobenzothiazines tested altered cell morphology, this undesired aspect was further investigated by exploring possible perturbation of lipid metabolism during compound treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
